Analysts’ Recent Ratings Changes for Minerva Neurosciences (NERV)

Minerva Neurosciences (NASDAQ: NERV) has recently received a number of price target changes and ratings updates:

• 11/18/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/10/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/6/2024 – Minerva Neurosciences had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
• 11/2/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/25/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/17/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/9/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/1/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 9/23/2024 – Minerva Neurosciences is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

Minerva Neurosciences Trading Up 4.2 %

Shares of NERV stock opened at $2.21 on Friday. Minerva Neurosciences, Inc. has a 1 year low of $2.07 and a 1 year high of $13.49. The stock has a 50 day simple moving average of $2.55 and a 200 day simple moving average of $2.78. The stock has a market cap of $15.45 million, a P/E ratio of -5.02 and a beta of 0.18.

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.